Results 261 to 270 of about 106,545 (283)
Some of the next articles are maybe not open access.

Imatinib and Pregnancy

Journal of Clinical Oncology, 2006
Abstract Animal studies with imatinib have shown it to be teratogenic, embryotoxic and to result in increased rates of post-implantation loss. As a consequence there are justifiable physician/patient concerns regarding the safety of tyrosine kinase inhibitors during pregnancy.
Ali, RIDVAN   +4 more
openaire   +5 more sources

Imatinib

Drugs, 2001
Imatinib inhibits the BCR-ABL tyrosine kinase created by the Philadelphia chromosome (Ph+) in chronic myeloid leukaemia (CML). Complete haematological responses were achieved in 88% of patients and major cytogenetic responses were detected in 49% of patients with chronic phase CML treated with oral imatinib 400 mg/day in a multicentre noncomparative ...
K, Lyseng-Williamson, B, Jarvis
openaire   +2 more sources

Imatinib and Hyperlipidemia

New England Journal of Medicine, 2005
To the Editor: We report on a series of nine patients with hyperlipidemia and either chronic myeloid leukemia or the hypereosinophilic syndrome, in eight of whom plasma lipid levels normalized within one month after imatinib therapy (at a dose of 400 mg daily) was started. All nine patients had hypercholesterolemia (mean plasma total cholesterol level,
GOTTARDI M   +2 more
openaire   +3 more sources

Imatinib, cheese and migraines

Leukemia & Lymphoma, 2020
Here we report a patient with maculopapular cutaneous mastocytosis who developed imatinib-induced cheese sensitivity manifest as migraine headaches.
Michael Woodfin   +4 more
openaire   +3 more sources

Imatinib-induced pseudoporphyria

Clinical and Experimental Dermatology, 2009
Imatinib, a synthetic tyrosine kinase inhibitor, is used as first-line therapy for chronic myeloid leukaemia. Imatinib treatment is associated with a variety of adverse effects, most of which are mild to moderate and generally abate after the first months of treatment.
Timmer-de Mik, L.   +4 more
openaire   +4 more sources

Imatinib Mesylate

2014
Imatinib (INN), marketed by Novartis as Gleevec (United States) or Glivec (Europe/Australia/Latin America), received Food & Drug Administration (FDA) approval in May 2001 and is a tyrosine kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.
Ahmed H. Bakheit   +2 more
openaire   +3 more sources

Imatinib resistance in CML

Cancer Letters, 2009
Imatinib is, at present, the first-choice treatment for patients with chronic myeloid leukaemia in chronic phase. Despite the impressive rate of complete haematological response and complete cytogenetical remissions, some cases show primary resistance or relapse after an initial response (secondary or acquired resistance).
VOLPE, Gisella   +3 more
openaire   +4 more sources

Quality of life on imatinib

Seminars in Hematology, 2003
Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL). This phase III international study evaluated QoL outcomes in 1,106 newly diagnosed patients with chronic-phase chronic myeloid leukemia (CML) who were randomized
Elizabeth A. Hahn   +1 more
openaire   +3 more sources

Imatinib Mesylate

2009
Imatinib mesylate (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly referred to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents, so-called small molecules. They have a high selectivity against a specific molecular target known to be the cause for the establishment and maintenance of the malignant phenotype ...
openaire   +6 more sources

The development and application of imatinib

Expert Opinion on Drug Safety, 2005
The hallmark characteristics of cancer include an unrestrained proliferation involving activation of growth signals, loss of negative regulation and dysfunctional apoptotic pathways. Targeting abnormal cell signalling pathways should provide a more selective approach to cancer treatment than conventional cytotoxic chemotherapy. Tyrosine kinases play an
Ian Judson, Robin L. Jones
openaire   +3 more sources

Home - About - Disclaimer - Privacy